SUPN

Supernus Inc

28.15

Nov 03 • 3:59 PM ET -13.77 (-32.85%)

28.53

Aftermarket • 6:45 PM ET +0.38 (1.35%)

Healthcare Drug Manufacturers - Specialty & Generic USA Mid NASD

Today, 7:30 AMMerger ticker reuse and $8.13 ex-dividend mechanically create SUPN’s apparent 33% premarket drop

Peers: ALKS NBIX ACAD AXSM COLL HRMY INDV JAZZ AMRX BIIB

| Held by: IJR IWM VTI VB VTI IJT VB SPSM VBK VXF

Scroll to Statements

Index	RUT
Market Cap	2.88B
Enterprise Value	3.07B
Income	450.00M
Sales	1.37B
Book/sh	-0.51
Cash/sh	2.99
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	Nov 03, 2026
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	838
IPO	May 01, 2012

P/E	7.79
Forward P/E	6.70
PEG	0.29
P/S	2.09
P/B	-
P/C	9.43
P/FCF	110.77
EV/EBITDA	4.85
EV/Sales	2.24
Quick Ratio	0.50
Current Ratio	0.62
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	3.61
EPS next Y	4.20
EPS next Q	0.99
EPS this Y	57.53%
EPS next Y	6.74%
EPS next 5Y	23.16%
EPS past 3/5Y	- -
Sales past 3/5Y	11.20% 13.88%
EPS Y/Y TTM	265.06%
Sales Y/Y TTM	16.44%
EPS Q/Q	244.87%
Sales Q/Q	13.38%
Earnings	Oct 29 BMO
EPS/Sales Surpr.	24.45% 8.09%

Insider Own	3.00%
Insider Trans	0.00%
Inst Own	97.23%
Inst Trans	2.29%
ROA	32.75%
ROE	-
ROIC	-
Gross Margin	85.08%
Oper. Margin	45.05%
Profit Margin	32.75%
SMA20	-30.74%
SMA50	-33.21%
SMA200	-40.33%
Trades

Shs Outstand	124.77M
Shs Float	121.03M
Short Float	3.34%
Short Ratio	4.42
Short Interest	4.04M
52W High	59.68 -52.83%
52W Low	37.54 -25.01%
Volatility	5.95% 4.67%
ATR (14)	2.80
RSI (14)	19.70
Beta	0.52
Rel Volume	9.89
Avg Volume	915.50K
Volume	9,053,171

Perf Week	-31.27%
Perf Month	-34.17%
Perf Quarter	-39.99%
Perf Half Y	-42.77%
Perf YTD	-43.36%
Perf Year	-49.46%
Perf 3Y	14.99%
Perf 5Y	-6.26%
Perf 10Y	55.52%
Recom	1.33
Target Price	48.67
Prev Close	41.92
Price	28.15
Change %	-32.85%

Consensus

Strong Buy

Avg. Price Target

$48.67

Implied Upside

+72.9%

Analysts9incl. previous ratings

Rating Distribution7 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 09, 2025	Upgrade	PPiper Sandler	Neutral → Overweight	$65	+130.9%
Jul 30, 2025	Upgrade	CCantor Fitzgerald	Neutral → Overweight	$42	+49.2%
Feb 19, 2025	Downgrade	CCantor Fitzgerald	Overweight → Neutral	$57 → $36	+27.9%
Jan 06, 2025	Initiated	CCantor Fitzgerald	Overweight	$57	+102.5%
Sep 11, 2024	Downgrade	PPiper Sandler	Overweight → Neutral	$41 → $36	+27.9%
Jan 03, 2023	Resumed	JJefferies	Buy	$44 → $45	+59.9%
Dec 01, 2021	Resumed	JJefferies	Buy	$40 → $44	+56.3%
Apr 13, 2021	Upgrade	JJefferies	Hold → Buy	$25 → $40	+42.1%
Jun 16, 2020	Upgrade	PPiper Sandler	Neutral → Overweight	$25 → $31	+10.1%
Jun 15, 2020	Resumed	JJefferies	Hold	$24	-14.7%
Nov 08, 2019	Downgrade	BBerenberg	Buy → Hold
Nov 07, 2019	Downgrade	SStifel	Buy → Hold	$55 → $23	-18.3%
Nov 06, 2019	Downgrade	JJefferies	Buy → Hold	$46 → $23	-18.3%
Nov 12, 2018	Reiterated	BB. Riley FBR	Buy	$68 → $65	+130.9%
Jan 18, 2018	Reiterated	BB. Riley FBR, Inc.	Buy	$54	+91.8%
Dec 28, 2017	Reiterated	BB. Riley FBR, Inc.	Buy	$50 → $54	+91.8%
Dec 04, 2017	Upgrade	JJanney	Neutral → Buy
Nov 08, 2017	Upgrade	SStifel	Hold → Buy	$47	+67.0%
Oct 19, 2017	Initiated	FFBR & Co.	Buy	$53	+88.3%
Sep 19, 2017	Downgrade	SStifel	Buy → Hold	$47	+67.0%

Nov-02-26 09:18AM	Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader (GlobeNewswire)
Oct-29-26 06:38PM	Supernus Ends Its Standalone Era With A Big Beat And Higher Guidance, But The Indivior Merger Now Drives The Story (Earnings Whispers)
04:42PM	Supernus: Q3 Earnings Snapshot (Associated Press)
04:05PM	Supernus Announces Third Quarter 2026 Financial Results (GlobeNewswire)
Oct-28-26 05:43PM	Updated Effective Date: Huron Consulting Group Set to Join S&P SmallCap 600 (PR Newswire)
08:30AM	Loading…
08:30AM	Chloe Kim Is Changing the Conversation Around ADHD in Women with Qelbree for 'Ms. Represented' Campaign (GlobeNewswire)
Oct-22-26 06:27PM	Huron Consulting stock rises on S&P SmallCap 600 addition (Investing.com)
06:08PM	MSG Rangers and Huron Consulting Group Set to Join S&P SmallCap 600 (PR Newswire)
06:55AM	Supernus Must Prove Its Standalone Engine Still Hums As Indivior Merger Nears (Earnings Whispers)
Oct-21-26 07:45PM	Supernus Announces Orphan Drug Exclusivity for ONAPGO (apomorphine HCl) (GlobeNewswire)
Oct-19-26 08:30AM	Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026 (GlobeNewswire) +5.17%
Sep-25-26 07:38AM	Are ITGR, BZH, SUPN Obtaining Fair Deals for their Shareholders? (PR Newswire)
Sep-02-26 04:30PM	Supernus Pharmaceuticals to Participate in September Investor Conferences (GlobeNewswire)
Aug-31-26 08:30AM	Chloe Kim Teams Up with Qelbree, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD (GlobeNewswire)
Aug-07-26 05:06PM	Are BOW, ATKR, SUPN Obtaining Fair Deals for their Shareholders? (PR Newswire)
01:05AM	Loading…
Aug-05-26 01:05AM	Supernus Pharmaceuticals Inc (SUPN) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com) +8.46%
Aug-04-26 07:57AM	Supernus and Indivior merge to create scaled, CNS-focused entity (Pharmaceutical Technology) -5.98%
Aug-03-26 01:41PM	Are SUPN, ITGR, ATKR, LNTH Obtaining Fair Deals for their Shareholders? (PR Newswire)
08:28AM	Supernus Shares Jump After Revenue Beat, Higher Guidance and Indivior Merger Announcement (InvestorsHub)
08:22AM	Supernus jumps premarket on merger deal; GameStop drops (Investing.com)
06:47AM	Supernus: Q2 Earnings Snapshot (Associated Press)
06:35AM	Supernus Announces Second Quarter 2026 Financial Results (GlobeNewswire)
06:30AM	Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale (GlobeNewswire)
Jul-22-26 05:05PM	Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026 (GlobeNewswire)
Jul-14-26 08:30AM	Supernus Celebrates Five-Year Anniversary of Qelbree FDA Approval, Continuing to Deliver on Real-World Experience in ADHD (GlobeNewswire)
May-27-26 04:30PM	Supernus Pharmaceuticals to Participate in June Investor Conferences (GlobeNewswire)
May-06-26 05:00PM	Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference (GlobeNewswire)
May-05-26 04:42PM	Supernus: Q1 Earnings Snapshot (Associated Press)
04:05PM	Supernus Announces First Quarter 2026 Financial Results (GlobeNewswire)
Apr-22-26 04:15PM	Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026 (GlobeNewswire)
05:00PM	Loading…
Apr-20-26 05:00PM	Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig (Business Wire)
Feb-25-26 01:07AM	Supernus Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat) +5.67%
12:03AM	Supernus Pharmaceuticals Inc (SUPN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Feb-24-26 10:30PM	Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks) +5.15%
09:55PM	Supernus Pharmaceuticals (SUPN) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
05:08PM	Supernus: Q4 Earnings Snapshot (Associated Press Finance)
04:21PM	Supernus Pharmaceuticals's (NASDAQ:SUPN) Q4 CY2025: Strong Sales (StockStory)
04:05PM	Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-23-26 06:15PM	Supernus Pharmaceuticals to Participate in March Investor Conferences (GlobeNewswire)
Feb-22-26 10:08PM	Supernus Pharmaceuticals (SUPN) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Feb-17-26 10:00AM	Earnings Preview: Supernus Pharmaceuticals (SUPN) Q4 Earnings Expected to Decline (Zacks)
Feb-16-26 11:04PM	3 Reasons to Avoid SUPN and 1 Stock to Buy Instead (StockStory)
Feb-12-26 04:35PM	Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026 (GlobeNewswire)
Feb-06-26 11:30AM	BIIB Beats on Q4 Earnings & Sales, Stock Gains on Upbeat '26 EPS View (Zacks)
Feb-03-26 07:56AM	New Drugs Take Center Stage as Biogen Heads Into Q4 Earnings (Zacks)
Dec-19-25 06:57AM	Strong Results Lifted Supernus Pharmaceuticals (SUPN) in Q3 (Insider Monkey)
Dec-03-25 04:05PM	Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference (GlobeNewswire)
Nov-21-25 04:06PM	Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
11:00AM	Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN) (StockStory)
Nov-12-25 04:05PM	Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London (GlobeNewswire)
Nov-11-25 12:36AM	5 Must-Read Analyst Questions From Supernus Pharmaceuticals's Q3 Earnings Call (StockStory)
Nov-06-25 08:07AM	Supernus Pharmaceuticals (SUPN) is Benefiting from Its Strength in Financial Position (Insider Monkey)
Nov-05-25 12:26PM	Why Supernus Pharmaceuticals (SUPN) Shares Are Trading Lower Today (StockStory) -17.35%
08:37AM	SUPN Q3 Deep Dive: Growth Drivers Offset By Supply Constraints and Integration Costs (StockStory)
12:03AM	Supernus Pharmaceuticals Inc (SUPN) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst ... (GuruFocus.com)
Nov-04-25 08:30PM	Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
05:20PM	Supernus Pharmaceuticals (SUPN) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
04:18PM	Supernus: Q3 Earnings Snapshot (Associated Press Finance)
04:12PM	Supernus Pharmaceuticals (NASDAQ:SUPN) Surprises With Strong Q3 (StockStory)
04:01PM	Supernus Announces Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-02-25 10:01PM	Supernus Pharmaceuticals (SUPN) Reports Q3: Everything You Need To Know Ahead Of Earnings (StockStory)
Oct-30-25 02:02PM	BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS View (Zacks)
10:00AM	Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-29-25 05:15PM	BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
12:00PM	Here's Why Supernus Pharmaceuticals (SUPN) is a Great Momentum Stock to Buy (Zacks)
09:35AM	Skyworks upgraded, UnitedHealth downgraded: Wall Street's top analyst calls (The Fly)
Oct-28-25 10:00AM	Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline (Zacks)
09:14AM	BridgeBio Pharma (BBIO) Soars 17.1%: Is Further Upside Left in the Stock? (Zacks)
Oct-27-25 09:15AM	Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run? (Zacks)
Oct-24-25 10:33AM	Will Biogen Beat on Q3 Earnings? Leqembi, Skyclarys Could Hold the Key (Zacks)
Oct-22-25 12:10PM	Why Supernus (SUPN) is Poised to Beat Earnings Estimates Again (Zacks)
Oct-21-25 05:00PM	Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 (GlobeNewswire)
Oct-16-25 03:23AM	Zacks.com featured highlights include United Natural Foods, Teladoc Health, Supernus and BRP (Zacks)
Oct-15-25 03:08PM	Can 4 Relative Price Strength Stocks Defy Market Swings? (Zacks)
Oct-13-25 12:00PM	Supernus Pharmaceuticals (SUPN) Is Up 2.81% in One Week: What You Should Know (Zacks)
Oct-12-25 11:31PM	Branded Pharmaceuticals Stocks Q2 Earnings Review: Supernus Pharmaceuticals (NASDAQ:SUPN) Shines (StockStory)
Oct-10-25 11:55AM	Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines? (Zacks)
09:15AM	Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run? (Zacks)
Oct-09-25 12:05PM	Supernus Pharmaceuticals (SUPN) Stock Is Up, What You Need To Know (StockStory)
Sep-25-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Supernus Pharmaceuticals (SUPN) is a Great Choice (Zacks)
Sep-23-25 09:15AM	Supernus Pharmaceuticals, Inc. (SUPN) Hit a 52 Week High, Can the Run Continue? (Zacks)
Sep-18-25 09:17AM	Biogen Gets EU Nod for First Postpartum Depression Drug (Zacks)
Sep-16-25 12:02AM	3 Reasons to Avoid SUPN and 1 Stock to Buy Instead (StockStory)
Aug-27-25 04:15PM	Supernus Pharmaceuticals to Participate in September Investor Conferences (GlobeNewswire)
Aug-13-25 12:12AM	5 Insightful Analyst Questions From Supernus Pharmaceuticals's Q2 Earnings Call (StockStory)
Aug-12-25 11:43PM	SUPN Q2 Deep Dive: Growth Drivers Shift to New Portfolio as Legacy Products Fade (StockStory)
Aug-11-25 08:00AM	Here's Third Avenue Small-Cap Value Fund's Update on Supernus Pharmaceuticals (SUPN) (Insider Monkey)
Aug-07-25 02:00PM	Supernus Pharmaceuticals Stock Scores RS Rating Upgrade (Investor's Business Daily)
Aug-06-25 01:20PM	Why Are Supernus Pharmaceuticals (SUPN) Shares Soaring Today (StockStory) +13.08%
03:27AM	Supernus Pharmaceuticals Inc (SUPN) Q2 2025 Earnings Call Highlights: Innovation and Strategic ... (GuruFocus.com)
Aug-05-25 08:30PM	Supernus (SUPN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
06:35PM	Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
06:18PM	Supernus Pharmaceuticals (NASDAQ:SUPN) Beats Expectations in Strong Q2, Guides for Strong Full-Year Sales (StockStory)
05:32PM	Supernus: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Supernus Announces Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-03-25 11:08PM	Supernus Pharmaceuticals (SUPN) Reports Earnings Tomorrow: What To Expect (StockStory)
Aug-01-25 07:09AM	Supernus strengthens neuropsychiatric portfolio with Sage Therapeutics (Pharmaceutical Technology)
Jul-31-25 10:48AM	Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up (Zacks)
08:44AM	Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics (GlobeNewswire)
Jul-30-25 04:05PM	Sage Therapeutics Announces Second Quarter 2025 Financial Results (Business Wire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Khattar Jack A.	President, CEO	Aug 12 '26	Option Exercise	0.00	29,849	0	1,270,993	Aug 14 05:12 PM
Rubin Jonathan	SVP, Chief Medical Officer	Aug 12 '26	Option Exercise	0.00	750	0	14,342	Aug 14 05:11 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Aug 12 '26	Option Exercise	0.00	2,500	0	19,795	Aug 14 05:11 PM
Mottola Frank	SVP, Chief Tech. Ops. Officer	Aug 12 '26	Option Exercise	0.00	1,650	0	20,341	Aug 14 05:10 PM
DEC TIMOTHY C	Senior Vice-President & CFO	Aug 12 '26	Option Exercise	0.00	1,250	0	9,733	Aug 14 05:09 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 17 '26	Option Exercise	38.51	50,000	1,925,537	67,044	Mar 18 05:18 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 16 '26	Option Exercise	33.62	50,000	1,681,205	67,044	Mar 18 05:18 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 18 '26	Option Exercise	39.40	7,250	285,650	24,294	Mar 18 05:18 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 17 '26	Sale	50.30	50,000	2,514,886	17,044	Mar 18 05:18 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 16 '26	Sale	50.28	50,000	2,513,925	17,044	Mar 18 05:18 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 18 '26	Sale	49.60	7,250	359,621	17,044	Mar 18 05:18 PM
PADMANABH P BHATT	Officer	Mar 17 '26	Proposed Sale	50.21	57,250	2,874,522		Mar 17 04:29 PM
PADMANABH P BHATT	Officer	Mar 16 '26	Proposed Sale	49.91	50,000	2,495,500		Mar 16 04:38 PM
Khattar Jack A.	President, CEO	Mar 13 '26	Sale	50.37	35,000	1,763,124	958,100	Mar 16 04:08 PM
Hudson Frederick M.	Director	Mar 12 '26	Sale	50.61	5,369	271,725	60,413	Mar 16 04:07 PM
THE KBT TRUST U/A DTD 12/30/20	Director	Mar 13 '26	Proposed Sale	50.46	35,000	1,766,100		Mar 13 04:22 PM
FREDERICK M HUDSON	Director	Mar 12 '26	Proposed Sale	50.62	5,369	271,752		Mar 12 04:06 PM
WILLIAM TODD HORICH	Officer	Mar 10 '26	Proposed Sale	55.00	4,439	244,145		Mar 10 04:18 PM
Khattar Jack A.	President, CEO	Mar 06 '26	Option Exercise	0.00	38,640	0	1,245,218	Mar 10 04:13 PM
Mottola Frank	SVP, Chief Tech. Ops. Officer	Mar 06 '26	Option Exercise	0.00	3,750	0	21,856	Mar 10 04:13 PM
Mottola Frank	SVP, Chief Tech. Ops. Officer	Mar 09 '26	Sale	53.65	1,623	87,074	18,440	Mar 10 04:13 PM
DEC TIMOTHY C	Senior Vice-President & CFO	Mar 06 '26	Option Exercise	0.00	6,000	0	9,682	Mar 10 04:12 PM
Horich William Todd	SVP, Commercial Operations	Mar 06 '26	Option Exercise	0.00	7,500	0	9,991	Mar 10 04:12 PM
Horich William Todd	SVP, Commercial Operations	Mar 10 '26	Sale	55.00	4,439	244,145	0	Mar 10 04:12 PM
Horich William Todd	SVP, Commercial Operations	Mar 09 '26	Sale	54.00	4,438	239,652	4,439	Mar 10 04:12 PM
WILLIAM TODD HORICH	Officer	Mar 09 '26	Proposed Sale	54.00	4,438	239,652		Mar 09 04:43 PM
FRANK MOTTOLA	Officer	Mar 09 '26	Proposed Sale	53.65	1,623	87,074		Mar 09 04:16 PM
GEMAYEL GEORGES	Director	Mar 06 '26	Option Exercise	25.30	7,905	199,996	36,064	Mar 09 04:06 PM
GEMAYEL GEORGES	Director	Mar 05 '26	Sale	53.71	10,000	537,100	28,159	Mar 09 04:06 PM
GEMAYEL GEORGES	Director	Mar 06 '26	Sale	53.00	8,787	465,711	27,277	Mar 09 04:06 PM
GEORGES GEMAYEL	Director	Mar 06 '26	Proposed Sale	53.01	8,787	465,771		Mar 06 04:24 PM
GEORGES GEMAYEL	Director	Mar 05 '26	Proposed Sale	53.71	10,000	537,117		Mar 05 04:04 PM
GEMAYEL GEORGES	Director	Feb 23 '26	Option Exercise	12.98	15,000	194,700	33,684	Feb 25 04:36 PM
Sensenig Bethany	Director	Feb 19 '26	Option Exercise	0.00	4,475	0	4,475	Feb 23 04:39 PM
Sensenig Bethany	Director	Feb 19 '26	Sale	51.01	4,475	228,265	0	Feb 23 04:39 PM
BETHANY SENSENIG	Director	Feb 19 '26	Proposed Sale	50.20	4,475	224,645		Feb 19 04:22 PM
Hudson Frederick M.	Director	Jan 09 '26	Option Exercise	12.98	15,000	194,700	61,307	Jan 12 04:09 PM
Mottola Frank	SVP, Chief Tech. Ops. Officer	Dec 19 '25	Option Exercise	28.82	20,000	576,500	30,496	Dec 22 04:04 PM
Mottola Frank	SVP, Chief Tech. Ops. Officer	Dec 19 '25	Sale	50.41	20,000	1,008,150	15,496	Dec 22 04:04 PM
FRANK MOTTOLA	Officer	Dec 19 '25	Proposed Sale	49.28	20,000	985,600		Dec 19 04:23 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Dec 18 '25	Option Exercise	0.00	1,500	0	15,218	Dec 19 04:05 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Dec 18 '25	Sale	44.44	710	31,552	14,508	Dec 19 04:05 PM
NEWHALL CHARLES W III	Director	Nov 21 '25	Option Exercise	12.98	15,000	194,700	119,644	Nov 24 06:16 PM

Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company was founded on December 23, 2014 and is headquartered in North Chesterfield, VA.

FounderMr. Jack A. Khattar M.B.A.

Senior VP & CFOMr. Timothy C. Dec

Chief Scientific Officer & Senior VP of Intellectual PropertyDr. Padmanabh P. Bhatt Ph.D.

Senior VP & Chief Technology Operations OfficerMr. Frank Mottola

M.D.Dr. Jonathan Rubin M.B.A.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SUPN

Supernus Inc

Upgrade your Finviz experience